First Safety Study in Humans of a Single Dose of CPG 52364

• Drug: Placebo Comparator: Cohort 1 Placebo
  
  Drug: placebo for cohort 1 as single dose
• Drug: 52364 3 mg
  
  3 mg capsule single dose administered orally as a single dose
• Drug: Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
  
  Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
• Drug: 52364 10 mg
  
  Drug: 52364 30 mg capsule as a single dose
• Drug: 52364 30 mg
  
  Drug: 52364 30 mg capsule administered as a single dose
• Drug: 52364 100 mg
  
  Drug 52364 100 mg capsule administered as a single dose
• Drug: 52364 1 mg
  
  1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose

• Experimental: Cohort 1 1mg
  
  Interventions:
  

  • Drug: Placebo Comparator: Cohort 1 Placebo
  • Drug: 52364 1 mg
• Experimental: Cohort 2
  
  Interventions:
  

  • Drug: 52364 3 mg
  • Drug: Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
• Experimental: Cohort 3
  
  Intervention: Drug: 52364 10 mg
• Experimental: Cohort 4
  
  Intervention: Drug: 52364 30 mg
• Experimental: Cohort 5
  
  Intervention: Drug: 52364 100 mg

Inclusion Criteria:

• Normal body mass index and weight
• No significant diseases in the medical history or clinically significant findings on physical exam, opthalmologic exam, clinical laboratory evaluations or 12-lead electrocardiogram

Exclusion Criteria:

• Current illness or history of medical condition affecting the body's function
• Use of any medication within 7 days, any immunosuppressive medication within 6 months, any investigational drug within 30 days or any vaccine or immunoglobulin within 90 days
• Use of any medications during the study
• Positive TB test
• Smoking within 6 months
• Pregnancy or risk of Pregnancy
• Alcohol or drug misuse within 60 days
• Sensitivity to quinazolines